Fig. 1
From: THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
THOR (cg11625005) is hypermethylated in malignant breast tissue and positively correlated with hTERT expression in breast carcinoma. A Schematic representation of the hTERT promoter region (GRCh37/hg19). The Illumina Infinium HumanMethylation450 array covers the area of interest with the probe cg11625005. THOR localizes between -159 and -591 base pairs from the TSS of the TERT promoter. The position of the probe cg11625005 used to evaluate THOR methylation status is shown (chr5:1,295,737). C250T (chr5:1,295,250) and C228T (chr5:1,295,228) represent TERT promoter mutations commonly found in cancer tissue. The scheme is not scaled. THOR-TERT hypermethylated oncologic region; TSS-transcription start site. Adapted from (Faleiro, Apolónio, et al., 2017). B Breast invasive carcinoma shows higher THOR methylation (cg11625005) when compared to benign breast tissue (P < 0.0001). C hTERT is differentially expressed in benign and malignant breast tissue (P < 0.0001) D and it is positively correlated with THOR methylation status (cg11625005) in breast cancer (r = 0.1626, P < 0.0001, Spearman correlation). In B. and C. statistical differences were assessed using the two-tailed Mann–Whitney U test